What is REVB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for REVB?

P/E (TTM) is n/a and 52-week range is $0.75 to $6.76 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s REVB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for REVB?

The company profile lists net income (TTM) near $-25M, EPS (TTM) near $-6.33 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Revelation Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 3.9M shares outstanding, ISIN US76135L8046 when available from company profile and filing metadata.

Revelation Biosciences Inc (REVB) Stock Analysis & Quote

Revelation Biosciences Inc

$REVB

Health Care · Biotechnology

IR Run Scenarios

$0.76

-1.81%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Revelation Biosciences, Inc. engages in the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Employees

Website

www.revbiosciences.com/

IPO

2020-10-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)